SwanBio Therapeutics

23 articles about SwanBio Therapeutics

• SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders

  11/20/2020

  SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors

• SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer

  6/1/2020

  SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske , D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20

• SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene Therapy for Neurological Diseases

  4/23/2020

  $52 million is being allocated to progress IND-enabling studies in adrenomyeloneuropathy (AMN) and grow the pipeline in rare, monogenic neurological diseases